-

Protocol First Joins Flatiron Health

Combination helps bridge the gap between real-world care and clinical research

NEW YORK & SALT LAKE CITY--(BUSINESS WIRE)--Protocol First, a software solutions provider focused on accelerating clinical research, has joined Flatiron Healthas a wholly owned subsidiary, the two companies announced today.

“This is a win-win for both companies,” said Carolyn Starrett, Flatiron CEO. “Flatiron and Protocol First share a common vision in which technology and software increasingly bridge the gap between real-world care and clinical research.”

Protocol First’s technology enhances research efficiency by breaking down silos between sites, study sponsors and contract research organizations (CROs). Effective Dec. 14, Protocol First’s employees and operations joined Flatiron’s Clinical Research business unit, which builds on Flatiron’s established leadership in real-world evidence with new technologies that better integrate research into everyday clinical care.

“Flatiron has deep expertise in unstructured-data processing, experience building software that integrates seamlessly into site workflows, and an engaged network of community and academic research sites,” said Alex Deyle, General Manager, Clinical Research at Flatiron. “Protocol First’s technology expands and accelerates our ability to drive much-needed innovation in clinical research.”

Protocol First aims to reduce the operational complexity of data collection and validation in clinical research by leveraging proven technologies and standards. The team, led by CEO Hugh Levaux and CTO Amit Shah, has developed several industry-defining software solutions that have been adopted by many leading CROs and biopharma companies. The technology is designed to handle the unique complexities of research in oncology as well as other disease areas. Plans are being developed to integrate the direct EHR-to-EDC connector application Clinical Pipe – already in use with major academic medical centers and health systems – with Flatiron’s OncoEMR, which is used by hundreds of community cancer centers across the U.S.

“We are very excited about this combination, which will take our technology to the next level, scaling and broadening its availability across the life sciences industry,” said Levaux, who joins Flatiron as Vice President, Clinical Research. “The transition will be seamless for our customers, and the future belongs to the patients we will all serve with even better solutions.”

About Flatiron

Flatiron Health is a healthtech company dedicated to helping cancer centers thrive and deliver better care for patients today and tomorrow. Through clinical and data science, we translate patient experiences into real-world evidence to improve treatment, inform policy, and advance research. Cancer is smart. Together, we can be smarter. Flatiron Health is an independent affiliate of the Roche Group. Flatiron.com @FlatironHealth

About Protocol First

Protocol First, Inc., founded in 2015 and headquartered in Salt Lake City, UT, develops next-generation technology solutions for complex clinical trials in the Life Sciences industry. In addition to its flagship Protocol First suite of cloud-based solutions (eProtocol, Source Upload and EDC), Protocol First has launched Clinical Pipe, the industry’s first connector app that offers system-agnostic EHR-to-EDC interoperability. The application supports major EHR and EDC systems including Epic, Cerner, and Athena, as well as Medidata Rave and its own P1 platform. For additional information visit www.protocolfirst.com.

Contacts

Media Contact
Barbara Rosen, Director, Corporate Communications, Flatiron Health
press@flatiron.com

Protocol First

Details
Headquarters: New York, NY
CEO: Nathan Hubbard
Employees: 2,500
Organization: PRI

Release Summary
Protocol First Joins Flatiron Health
Release Versions

Contacts

Media Contact
Barbara Rosen, Director, Corporate Communications, Flatiron Health
press@flatiron.com

More News From Protocol First

Flatiron Health Brings 25+ Research Acceptances and Next-Generation Capabilities to ASCO 2026

NEW YORK--(BUSINESS WIRE)--Flatiron Health today announced its presence at the American Society of Clinical Oncology (ASCO) Annual Meeting happening from May 29 - June 2, 2026, in Chicago, Illinois. Flatiron's high-quality real-world data and innovative research capabilities are featured across 25+ research acceptances, including 14 Flatiron-authored poster presentations and online publications. Flatiron’s presence at ASCO 2026 closely follows the launch of Flatiron Telescope, a multi-agent ada...

New Research Confirms Data Quality as the Defining Priority Across the Real-World Evidence Landscape

NEW YORK--(BUSINESS WIRE)--As oncology grows more complex and the pace of innovation accelerates, life sciences organizations are placing a premium on high-quality, complete, and scalable real-world data. New insights from two independent surveys confirm that data quality and cohort scale are now prerequisites for confident decision-making and insight generation, especially as the industry evolves from retrospective analysis to predictive and AI-driven applications. A survey conducted by Deloit...

Flatiron Health Launches Flatiron Telescope, a New AI Platform Delivering Oncology Insights in Minutes

NEW YORK--(BUSINESS WIRE)--Flatiron Health today announced the launch of Flatiron Telescope, a next-generation AI-powered platform designed to help life sciences teams and researchers find the right patients faster, assess study feasibility in real time, and generate oncology insights on demand. Built on Flatiron’s industry-leading real-world data and powered by its multi-agent adaptive analytics engine, Flatiron Telescope enables teams across clinical development, RWE, and commercial functions...
Back to Newsroom